Effects of antihistamine on up-regulation of histamine H1 receptor mRNA in the nasal mucosa of patients with pollinosis induced by controlled cedar pollen challenge in an environmental exposure unit  by Kitamura, Yoshiaki et al.
ble at ScienceDirect
Journal of Pharmacological Sciences 129 (2015) 183e187Contents lists availaHOSTED BY
Journal of Pharmacological Sciences
journal homepage: www.elsevier .com/locate/ jphsFull paperEffects of antihistamine on up-regulation of histamine H1 receptor
mRNA in the nasal mucosa of patients with pollinosis induced by
controlled cedar pollen challenge in an environmental exposure unit
Yoshiaki Kitamura a, *, 1, Hideyuki Nakagawa a, 1, Tatsuya Fujii a, Takema Sakoda b,
Tadao Enomoto c, Hiroyuki Mizuguchi d, Hiroyuki Fukui e, Noriaki Takeda a
a Department of Otolaryngology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
b Department of Otolaryngology, Rinku General Medical Center, Osaka, Japan
c NPO Japan Health Promotion Supporting Network, Wakayama, Japan
d Department of Molecular Pharmacology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
e Department of Molecular Studies for Incurable Diseases, Institute of Biomedical Sciences, Tokushima University Graduate School,
Tokushima, Japana r t i c l e i n f o
Article history:
Received 4 August 2015
Received in revised form
30 September 2015
Accepted 19 October 2015
Available online 30 October 2015
Keywords:
Histamine H1 receptor
Antihistamines
Allergic rhinitis
Cedar pollinosis
Enviromental exposure unit* Corresponding author. Department of Otolaryngo
Sciences, Tokushima University Graduate School, 3-
770-8503, Japan. Tel.: þ81 88 633 7169; fax: þ81 88
E-mail address: ykitamura@tokushima-u.ac.jp (Y.
Peer review under responsibility of Japanese Pha
1 Yoshiaki Kitamura and Hideyuki Nakagawa contr
http://dx.doi.org/10.1016/j.jphs.2015.10.007
1347-8613/© 2015 Japanese Pharmacological Society
creativecommons.org/licenses/by-nc-nd/4.0/).a b s t r a c t
In the present study, we examined the effects of antihistamine on the up-regulation of H1R mRNA in the
nasal mucosa of patients with pollinosis induced by controlled exposure to pollen using an environ-
mental exposure unit. Out of 20 patients, we designated 14 responders, whose levels of H1R mRNA in the
nasal mucosa were increased after the ﬁrst pollen exposure and excluded 6 non-responders. Accordingly,
the ﬁrst exposure to pollen without treatment signiﬁcantly induced both nasal symptoms and the up-
regulation of H1R mRNA in the nasal mucosa of the responders. Subsequently, prophylactic adminis-
tration of antihistamine prior to the second pollen exposure signiﬁcantly inhibited both of the above
effects in the responders. Moreover, the nasal expression of H1R mRNA before the second pollen
exposure in the responders pretreated with antihistamine was signiﬁcantly decreased, as compared with
that before the ﬁrst pollen exposure without treatment. These ﬁndings suggest that antihistamines
suppressed histamine-induced transcriptional activation of H1R gene in the nasal mucosa, in addition to
their blocking effect against histamine on H1R, resulting in a decrease of nasal symptoms. These ﬁndings
further suggest that by their inverse agonistic activity, antihistamines suppress the basal transcription of
nasal H1R in the absence of histamine in responders.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Allergic rhinitis is one of the most common IgE-mediated dis-
eases and recent reports have shown an increase in its prevalence
(1). On the other hand, histamine is a major chemical mediator that
induces nasal allergy symptoms through its action on histamine H1
receptor (H1R). Moreover, the strength of H1R signaling that is
involved in nasal symptoms depends on the H1R expression levellogy, Institute of Biomedical
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633 7170.
Kitamura).
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. Production and hosting by Else(2). In fact, it was reported that the expression of H1R mRNA was
up-regulated in the nasal mucosa of patients with pollinosis (3,4).
Antihistamines are classiﬁed as neutral antagonists or inverse
agonists of H1R. Neutral antagonists antagonize histamine by
blocking its binding with H1R, whereas inverse agonists not only
antagonize histamine on H1R, but also suppress constitutive H1R
activity in the absence of histamine (5,6). We also demonstrated
that inverse agonist of H1R also suppressed the basal transcription
of H1R in the absence of histamine (7,8).
In our previous study using HeLa cells, we reported that hista-
mine increased the expression of H1R mRNA, while antihistamine
suppressed its up-regulation (9). We also reported an animal model
of nasal allergy using toluene-2,4-diisocynate (TDI)-sensitized rat,
and showed that intranasal application of TDI to the nasal mucosa
induced nasal symptoms together with an increase of H1R mRNAvier B.V. This is an open access article under the CC BY-NC-ND license (http://
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effects (10). Compounds that suppressed the up-regulation of H1R
gene expression also alleviated nasal symptoms in TDI-sensitized
rats (11e16). In another study, we demonstrated that the gene
expression of H1R is up-regulated in patients with pollinosis during
the pollen season, and its expression level correlated with the
severity of nasal symptoms (17). We also showed that prophylactic
administration of antihistamines decreased H1R gene up-
regulation with suppression of nasal symptoms (17).
However, it is difﬁcult to evaluate the efﬁcacy of the anti-
allergic drugs in patients with pollinosis under natural exposure
to pollen, because of the unpredictability of various parameters
such as pollen concentration, pollen antigenicity and weather
conditions. To overcome these limitations, environmental expo-
sure units (EEU) were developed to meet the criteria of stable
environmental conditions including temperature, humidity and
pollen concentration, and reproducibility of pollen-induced nasal
symptoms (18e20).
In the present study, an attempt was made to examine whether
controlled exposure to cedar pollenwithin the EEU induces the up-
regulation of H1R mRNA in the nasal mucosa of patients with
pollinosis. We then examined the effect of ebastine, a representa-
tive antihistaminewith inverse agonistic activity (7) administration
prior to pollen exposure on the up-regulation of H1R mRNA of the
nasal mucosa.2. Methods
2.1. Patients
The present study included 20 patients with Japanese cedar
pollinosis (7 men and 13 women; 30e57 years old; mean age:
45.3 ± 1.5). All showed positive CAP-radioallergosorbent test
(>class 2) with serum allergen-speciﬁc IgE against cedar pollen
(mean class: 3.45 ± 0.23). They did not take any anti-allergic drugs
during the period of this study, which was conducted out of the
pollen season.2.2. Study design
After the ﬁrst exposure to cedar pollen, we divided the patients
into two groups: the responder group and non-responder group,
based on their changes in the expression levels of H1R gene in the
nasal mucosa. Accordingly, the responder group included 14 pa-
tients (5 men and 9 women; 36e57 years old; mean age:
46.0 ± 1.7; mean class of cedar pollen: 3.50 ± 0.29; mean number
of eosinophils: 196 ± 98/ml), who showed increased levels of H1R
mRNA after the ﬁrst pollen exposure, while the non-responder
group included 6 patients (2 men and 4 women; 30e54 years
old; mean age: 43.7 ± 3.3 years; mean class of cedar pollen:
3.33 ± 0.42; mean number of eosinophils: 324 ± 169/ml), whose
levels of H1R mRNA were not increased after the ﬁrst pollen
exposure. The mean class of cedar pollen and mean number of
eosinophils in the responder patients was not different from that
in the non-responder patients. After a washout period for 3
months, the 14 responder patients were exclusively exposed to
cedar pollen again. Before the second pollen exposure, these pa-
tients were treated with oral administration of ebastine, an anti-
histamine, at a daily dose of 10 mg, p.o. for 3 days prior to the
exposure (Fig. 1a).
This study was approved by the Ethical Committees of
Tokushima University Hospital, and a written informed consent
was obtained from each patient prior to the study.2.3. Pollen exposure in the EEU
The study was performed out of the Japanese cedar pollen
season within the EEU in Wakayama City. The EEU was maintained
under comfortable conditions of temperature (20e26 C) and
relative humidity (50e65%). Patients were exposed to cedar pollen
at the concentration of 8000 grains/m3 for 3 h in the EEU, which
was enough to induce manifest nasal symptoms in our previous
study (18).
2.4. Evaluation of nasal symptoms
Nasal symptoms of sneezing and nasal dischargewere evaluated
30 min before the pollen exposure and every 30 min during the
exposure for 3 h (Fig. 1b). They were scored according to the fre-
quency of episodes of sneezing and nose-blowing.
2.5. Real-time quantitative RT-PCR
The scrapings of the nasal mucosa were obtained immediately
before and after the pollen exposure by scratching the surface of
each patients' inferior nasal conchawith a small spatula under local
anesthesia with 4% lidocaine (Fig. 1b). They were frozen in RNA-
later® (Applied Biosystems, Foster City, CA, USA) and stored in a
tube at 80 C until use. Total RNA was isolated using the
RNAqueous-Micro Kit (Applied Biosystems) in accordance with the
manufacturer's instructions. RNA samples were reverse-
transcribed to cDNA using a High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems). TaqManprimers and probewere
designed using Primer Express primer design software (Applied
Biosystems). The sequences of the H1R primers were as follows:
sense primer, 50-CAGAGGATCAGATGTTAGGTGATAGC- 30; antisense
primer, 50-AGCGGAGCCTCTTCCAAGTAA- 30. The sequence of the
probe was as follows: FAM-CTTCTCTCGAACGGACTCAGATACCACC-
TAMRA. The PUM1 primer and probe kit (Hs 00206469-m1,
Applied Biosystems) was used as an internal standard (17). The
transcripts were used for a 40-cycle, 3-step polymerase chain re-
action (PCR) with the GeneAmp 7300 Sequence Detection System
(Applied Biosystems). The size and reaction speciﬁcity of amplicon
were conﬁrmed by agarose gel electrophoresis. Identiﬁcation of the
PCR products was carried out using a genetic analysis system
(SEQ8000; Beckman Coulter, Inc., Fullerton, CA, USA).
2.6. Statistical analysis
The results are shown as mean ± standard deviation (SD). Sta-
tistical analysis was performed by the paired t-test or the Wilcoxon
signed-ranks test, and P values of <0.05 were considered to be
statistically signiﬁcant.
3. Results
Controlled exposure to Japanese cedar pollen for 3 h in the EEU
induced the up-regulation of H1R mRNA in the nasal mucosa of 14
patients (pre-exposure: 1.32± 0.74, post-exposure: 2.80± 2.18with
p < 0.01 vs. pre-exposure), but not in 6 others (pre-exposure:
2.49 ± 1.55, post-exposure: 1.06 ± 0.28 with p < 0.05 vs. post-
exposure of 14 patients) (Fig. 2). Thus, we designated the former
patients as responders and investigated the effect of ebastine on
their pollen exposure-induced nasal symptoms and up-regulation
of H1R mRNA in the nasal mucosa. The ﬁrst pollen exposure
signiﬁcantly increased the sum of sneezing and watery rhinorrhea
scores at 30, 120, 150 and 180 min in the responder group (pre-
exposure: 0.64 ± 1.39, 120 min after provocation: 4.86 ± 4.38,
p < 0.01 vs. pre-exposure, 180 min after exposure: 3.86 ± 2.30,
20 patients with 
pollinosis
non-responders
(6 patients)
1st pollen 
exposure in the 
EEU (3 h)
2nd pollen 
exposure in the 
EEU (3 h)
0 days-3
responders
(14 patients) washout
-2 -1
ebastine
(10 mg/day)
(a) Study Design
(b) Pollen exposure in the EEU
min
EEU (3 h)
0-30 60 120 180
nasal score evaluation
nasal mucosa scraping
Fig. 1. (a) Study design. Twenty patients were exposed to cedar pollen in the EEU for 3 h. After a wash-out period, 14 responder patients whose levels of H1R mRNA in the nasal
mucosa were increased after the 1st pollen exposure were treated with oral administration of ebastine once a daily for 3 day, and then exposed to pollen for 3 h. (b) Pollen exposure
in EEU. Nasal symptoms were evaluated 30 min before pollen exposure and every 30 min during pollen exposure in the EEU. Before and after the exposure, the scrapings of the nasal
mucosa were obtained, and H1R mRNA was measured.
Fig. 2. Effect of the 1st exposure of cedar pollen for 3 h on levels of H1R mRNA in nasal
mucosa of 20 patients with pollinosis. Black lines: 14 responder patients whose levels
of H1R mRNA were increased after the exposure. Gray lines: 6 non-responder patients
whose levels of H1R mRNA were not increased after the exposure. n ¼ 20.
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exposure did not change the nasal symptom scores (pre-exposure:
0.33 ± 0.52, 120 min after exposure: 5.00 ± 5.40, 180 min after
exposure: 3.67 ± 2.34) in 6 non-responder group that was
excluded. Three months later to wash out the aftereffect of 1stFig. 3. Effects of the ﬁrst pollen exposure without treatment and the second exposure
after prophylactic administration of antihistamine for 3 days on the sum of sneezing
and rhinorrhea scores in the 14 responder patients with pollinosis. A: 1st exposure
without treatment;-: 2nd exposure after prophylactic administration of ebastine for
3 days. *P < 0.05, **P < 0.01 vs. pre-1st exposure, ##p < 0.01 vs. 1st exposure. n ¼ 14.
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dose of 10 mg was given to these 14 responder patients for 3 days
prior to the second pollen exposure. This signiﬁcantly decreased
the nasal symptom scores at 120, 150 and 180 min after the pollen
exposure, in comparison with those induced by the ﬁrst exposure
(Fig. 3).
The ﬁrst pollen exposure signiﬁcantly increased the levels of
H1R mRNA in the nasal mucosa of the responder patients, whereas
the ebastine treatment suppressed the pollen exposure-induced
up-regulation of H1R mRNA (Fig. 4). Accordingly, the levels of
H1R mRNA after the second pollen exposure was signiﬁcantly
decreased, in comparison with those after the ﬁrst pollen exposure
in the responders.
Moreover, the levels of H1R mRNA in the nasal mucosa of the
responder patients pretreated with ebastine were signiﬁcantly
decreased before the second pollen exposure, in comparison with
those without ebastine treatment before the ﬁrst pollen exposure
(Fig. 4).
4. Discussion
In the present study, we showed that the controlled exposure to
Japanese cedar pollen in the EEU induced both nasal symptoms and
up-regulation of H1R mRNA in nasal mucosa of 14 responders
among the 20 patients with pollinosis. Previously, we reported that
in HeLa cells, histamine-induced up-regulation of H1R mRNA
through the protein kinase C-d (PKCd)/extracellular signal-
regulated kinase/poly (ADP-ribose) polymerase-1 signaling
pathway (9,21,22). We also reported that H1R in the nasal mucosa
was up-regulated at both mRNA and protein levels after provoca-
tion in the animal model of allergic rhinitis (11). We further showed
that the elevation of the receptor expression increases histamine
signaling involved in nasal symptoms (2). Taken together, the
present ﬁnding suggests that in IgE-mediated response to pollen
inhalation, histamine released from mast cells stimulates H1R in
the nasal mucosa, resulting in both induction of nasal symptoms
and up-regulation of H1R in the responder patients.
In the responder patients who had been prophylactically
administrated ebastine for 3 days, the second pollen exposure
induced neither nasal symptoms nor the up-regulation of H1R
mRNA expression in nasal mucosa. In our previous study with HeLa
cells, we reported that antihistamine inhibited histamine-inducedFig. 4. Effects of the ﬁrst pollen exposure without treatment and the second exposure
after prophylactic administration of antihistamine for 3 days on the levels of H1R
mRNA in nasal mucosa of the 14 responder patients with pollinosis. Black columns:
pre-1st or 2nd pollen exposure. Gray columns: post-1st or 2nd pollen exposure.
**P < 0.01, ##P < 0.01 vs. pre-1st pollen exposure. ##P < 0.01 vs. post-1st pollen
exposure. n ¼ 14.up-regulation of H1R mRNA (9). We also showed that preseasonal
prophylactic treatment with antihistamine suppressed the gene
expression of H1R in the nasal mucosa of patients with pollinosis
during the peak pollen period (17). Taken together, the present
ﬁndings suggest that prophylactic administration of ebastine sup-
pressed the released histamine-induced up-regulation of H1R gene
expression in the nasal mucosa of the responder patients after the
second pollen exposure. The present ﬁndings also suggest that
antihistamine reduced histamine signaling by their suppressive
effect on histamine-induced transcriptional activation of H1R, in
addition to their blocking effect against histamine on H1R, resulting
in a decrease of nasal allergy symptoms.
In the responder patients, administration of ebastine for 3 days
prior to the second pollen exposure also decreased the gene
expression of H1R in the nasal mucosa, as compared with that
without ebastine treatment before the ﬁrst pollen exposure. Ac-
cording to the two-state model of H1R, active and inactive forms of
H1R coexist in a dynamic equilibrium, and the inverse agonist of
H1R stabilizes the inactive form of H1R, shifting the equilibrium
toward the inactive state in the absence of histamine (5,6). We
demonstrated that inverse agonist of H1R also suppressed the basal
transcription of H1R in the absence of histamine (7,8). As reported
previously, ebastine is an inverse agonist of H1R (7), the present
ﬁnding suggests that antihistamine with inverse agonistic activity
suppresses the basal transcription of H1R in the nasal mucosa in the
absence of histamine, resulting in the down-regulation of nasal
H1R gene expression in absence of pollen exposure.
However, the exposure to pollen did not induce the up-
regulation of H1R gene expression in the nasal mucosa of the
non-responder patients. Their nasal symptom scores increased af-
ter the pollen exposure, but the increase did not reach statistical
signiﬁcance. Thus, it is suggested that in the non-responder pa-
tients, the pollen exposure did not release sufﬁcient amount of
histamine to induce up-regulation of H1R gene expression, despite
a positive allergen-speciﬁc IgE against cedar pollen in their serum.
However, there was no signiﬁcant correlation between nasal
symptom scores and the levels of H1R mRNA in nasal mucosa,
probably because nasal symptoms are partially mediated by
chemical mediators other than histamine.
In conclusion, the controlled exposure to cedar pollen in the EEU
induced both nasal symptoms and up-regulation of H1R mRNA in
the nasal mucosa of the responder patients with pollinosis, and the
prophylactic administration with an inverse agonist of H1R
suppressed both pollen exposure-induced nasal symptoms and up-
regulation of nasal H1R mRNA. Moreover, prophylactic adminis-
tration with inverse agonist of H1R down-regulated the basal gene
expression of H1R mRNA in the nasal mucosa without pollen
exposure. These ﬁndings suggest that antihistamines with inverse
agonistic activity inhibit nasal symptoms in patients with pollinosis
through three different mechanisms: 1) blocking histamine effect
on H1R, 2) suppressive effect on histamine-induced transcriptional
activation of H1R, and 3) suppressive effect on the basal tran-
scription of H1R in the absence of histamine.Conﬂict of interest
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